Received Apr 23, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HIBV | HIB (HIBERIX) | GLAXOSMITHKLINE BIOLOGICALS | 3 | 9AC73 | — |
| MMR | MEASLES + MUMPS + RUBELLA (PRIORIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | T543P | — |
Hiberix, Priorix-Use of non-approved diluent to reconstitute and administer to patient. Priorix underage administration of vaccine.; Hiberix, Priorix-Use of non-approved diluent to reconstitute and administer to patient. Priorix underage administration of vaccine.; Underage administration of Priorix; This non-serious case was reported by a other health professional via call center representative and described the occurrence of inappropriate dose of vaccine administered in a 6-month-old male patient who received Hib (Hiberix) (batch number 9AC73, expiry date 09-DEC-2026) for prophylaxis. Co-suspect products included MMR (Priorix) (batch number T543P, expiry date 19-MAR-2027) for prophylaxis. On 01-APR-2026, the patient received the 3rd dose of Hiberix and Priorix. On 01-APR-2026, an unknown time after receiving Hiberix and Priorix, the patient experienced inappropriate dose of vaccine administered (Verbatim: Hiberix, Priorix-Use of non-approved diluent to reconstitute and administer to patient. Priorix underage administration of vaccine.), inappropriate preparation of medication (Verbatim: Hiberix, Priorix-Use of non-approved diluent to reconstitute and administer to patient. Priorix underage administration of vaccine.) and inappropriate age at vaccine administration (Verbatim: Underage administration of Priorix ). The outcome of the inappropriate dose of vaccine administered, inappropriate preparation of medication and inappropriate age at vaccine administration were not applicable. It was unknown if the reporter considered the inappropriate age at vaccine administration to be related to Priorix. It was unknown if the company considered the inappropriate age at vaccine administration to be related to Priorix. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date 13-APR-2026 and 14-APR-2026 The patient was administered Priorix reconstituted with a Hiberix GSK diluent for dose 3 in the series. The same patient was administered Hiberix vaccine reconstituted with Priorix GSK diluent on 01Apr2026. The Medical assistant stated the vaccines were administered as the third dose in the series. It was not clearly defined if this included a third dose of Priorix or if the health care professional was only referring to a third dose in the Hiberix series. No further details provided. The reporter consented to follow up.